494 related articles for article (PubMed ID: 31279304)
41. Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma.
Rubenstein JL; Geng H; Fraser EJ; Formaker P; Chen L; Sharma J; Killea P; Choi K; Ventura J; Kurhanewicz J; Lowell C; Hwang J; Treseler P; Sneed PK; Li J; Wang X; Chen N; Gangoiti J; Munster PN; Damato B
Blood Adv; 2018 Jul; 2(13):1595-1607. PubMed ID: 29986852
[TBL] [Abstract][Full Text] [Related]
42. Salvage therapy with bendamustine for methotrexate refractory recurrent primary CNS lymphoma: a retrospective case series.
Chamberlain MC
J Neurooncol; 2014 May; 118(1):155-62. PubMed ID: 24584709
[TBL] [Abstract][Full Text] [Related]
43. A single centre study of the treatment of relapsed primary central nervous system lymphoma (PCNSL) with single agent temozolomide.
Wong SF; Gan HK; Cher L
J Clin Neurosci; 2012 Nov; 19(11):1501-5. PubMed ID: 22995759
[TBL] [Abstract][Full Text] [Related]
44. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis.
Abrey LE; Moskowitz CH; Mason WP; Crump M; Stewart D; Forsyth P; Paleologos N; Correa DD; Anderson ND; Caron D; Zelenetz A; Nimer SD; DeAngelis LM
J Clin Oncol; 2003 Nov; 21(22):4151-6. PubMed ID: 14615443
[TBL] [Abstract][Full Text] [Related]
45. Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse.
Bernard S; Goldwirt L; Amorim S; Brice P; Brière J; de Kerviler E; Mourah S; Sauvageon H; Thieblemont C
Blood; 2015 Oct; 126(14):1695-8. PubMed ID: 26239089
[TBL] [Abstract][Full Text] [Related]
46. Lymphomas of Central Nervous System.
Yokogami K; Azuma M; Takeshima H; Hirai T
Adv Exp Med Biol; 2023; 1405():527-543. PubMed ID: 37452952
[TBL] [Abstract][Full Text] [Related]
47. Long-term outcomes of combined intravitreal methotrexate and systemic high-dose methotrexate therapy in vitreoretinal lymphoma.
Cheng CL; Yeh PT; Fang WQ; Ma WL; Hou HA; Tsai CH; Lin CP; Tien HF
Cancer Med; 2023 Apr; 12(7):8102-8111. PubMed ID: 36602288
[TBL] [Abstract][Full Text] [Related]
48. Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004).
Wang M; Schuster SJ; Phillips T; Lossos IS; Goy A; Rule S; Hamadani M; Ghosh N; Reeder CB; Barnett E; Bravo MC; Martin P
J Hematol Oncol; 2017 Nov; 10(1):171. PubMed ID: 29096668
[TBL] [Abstract][Full Text] [Related]
49. Characteristics and Outcomes of Primary Central Nervous System Lymphoma: A Retrospective Study of 91 Cases in a Chinese Population.
Mao C; Chen F; Li Y; Jiang X; Liu S; Guo H; Huang L; Wei X; Liang Z; Li W; Tang K
World Neurosurg; 2019 Mar; 123():e15-e24. PubMed ID: 30326304
[TBL] [Abstract][Full Text] [Related]
50. Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial.
Jerkeman M; Eskelund CW; Hutchings M; Räty R; Wader KF; Laurell A; Toldbod H; Pedersen LB; Niemann CU; Dahl C; Kuitunen H; Geisler CH; Grønbæk K; Kolstad A
Lancet Haematol; 2018 Mar; 5(3):e109-e116. PubMed ID: 29396091
[TBL] [Abstract][Full Text] [Related]
51. Late relapse in primary central nervous system lymphoma: clonal persistence.
Nayak L; Hedvat C; Rosenblum MK; Abrey LE; DeAngelis LM
Neuro Oncol; 2011 May; 13(5):525-9. PubMed ID: 21372070
[TBL] [Abstract][Full Text] [Related]
52. Pemetrexed in the treatment of relapsed/refractory primary central nervous system lymphoma.
Raizer JJ; Rademaker A; Evens AM; Rice L; Schwartz M; Chandler JP; Getch CC; Tellez C; Grimm SA
Cancer; 2012 Aug; 118(15):3743-8. PubMed ID: 22179954
[TBL] [Abstract][Full Text] [Related]
53. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
Chanan-Khan A; Cramer P; Demirkan F; Fraser G; Silva RS; Grosicki S; Pristupa A; Janssens A; Mayer J; Bartlett NL; Dilhuydy MS; Pylypenko H; Loscertales J; Avigdor A; Rule S; Villa D; Samoilova O; Panagiotidis P; Goy A; Mato A; Pavlovsky MA; Karlsson C; Mahler M; Salman M; Sun S; Phelps C; Balasubramanian S; Howes A; Hallek M;
Lancet Oncol; 2016 Feb; 17(2):200-211. PubMed ID: 26655421
[TBL] [Abstract][Full Text] [Related]
54. Systemic relapses of primary CNS lymphomas (PCNSL): a LOC network study.
Dufour J; Choquet S; Hoang-Xuan K; Schmitt A; Ahle G; Houot R; Taillandier L; Gressin R; Casasnovas O; Marolleau JP; Tamburini J; Serrier C; Perez E; Paillassa J; Gyan E; Chauchet A; Ursu R; Kas A; Soussain C; Houillier C
Ann Hematol; 2023 May; 102(5):1159-1169. PubMed ID: 36991231
[TBL] [Abstract][Full Text] [Related]
55. Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.
Younes A; Sehn LH; Johnson P; Zinzani PL; Hong X; Zhu J; Patti C; Belada D; Samoilova O; Suh C; Leppä S; Rai S; Turgut M; Jurczak W; Cheung MC; Gurion R; Yeh SP; Lopez-Hernandez A; Dührsen U; Thieblemont C; Chiattone CS; Balasubramanian S; Carey J; Liu G; Shreeve SM; Sun S; Zhuang SH; Vermeulen J; Staudt LM; Wilson W;
J Clin Oncol; 2019 May; 37(15):1285-1295. PubMed ID: 30901302
[TBL] [Abstract][Full Text] [Related]
56. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study.
Younes A; Brody J; Carpio C; Lopez-Guillermo A; Ben-Yehuda D; Ferhanoglu B; Nagler A; Ozcan M; Avivi I; Bosch F; Caballero Barrigón MD; Hellmann A; Kuss B; Ma DDF; Demirkan F; Yağci M; Horowitz NA; Marlton P; Cordoba R; Wrobel T; Buglio D; Streit M; Hodkinson BP; Schaffer M; Alvarez J; Ceulemans R; Balasubramanian S; de Jong J; Wang SS; Fourneau N; Jurczak W
Lancet Haematol; 2019 Feb; 6(2):e67-e78. PubMed ID: 30642819
[TBL] [Abstract][Full Text] [Related]
57. Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort.
Winqvist M; Andersson PO; Asklid A; Karlsson K; Karlsson C; Lauri B; Lundin J; Mattsson M; Norin S; Sandstedt A; Rosenquist R; Späth F; Hansson L; Österborg A;
Haematologica; 2019 May; 104(5):e208-e210. PubMed ID: 30514799
[No Abstract] [Full Text] [Related]
58. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.
Moreno C; Greil R; Demirkan F; Tedeschi A; Anz B; Larratt L; Simkovic M; Samoilova O; Novak J; Ben-Yehuda D; Strugov V; Gill D; Gribben JG; Hsu E; Lih CJ; Zhou C; Clow F; James DF; Styles L; Flinn IW
Lancet Oncol; 2019 Jan; 20(1):43-56. PubMed ID: 30522969
[TBL] [Abstract][Full Text] [Related]
59. A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of the final analysis.
Yoon SE; Kim SJ; Yoon DH; Koh Y; Mun YC; Do YR; Choi YS; Yang DH; Kim MK; Lee GW; Suh C; Ko YH; Kim WS
Ann Hematol; 2020 Jun; 99(6):1283-1291. PubMed ID: 32333154
[TBL] [Abstract][Full Text] [Related]
60. Patterns of response and relapse in primary CNS lymphomas after first-line chemotherapy: imaging analysis of the ANOCEF-GOELAMS prospective randomized trial.
Tabouret E; Houillier C; Martin-Duverneuil N; Blonski M; Soussain C; Ghesquières H; Houot R; Larrieu D; Soubeyran P; Gressin R; Gyan E; Chinot O; Taillandier L; Choquet S; Alentorn A; Leclercq D; Omuro A; Tanguy ML; Hoang-Xuan K
Neuro Oncol; 2017 Mar; 19(3):422-429. PubMed ID: 27994065
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]